Cargando…

Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization

Cancer neoantigens that arise from somatic mutations have emerged as important targets for personalized immunization. Here, we report an improved overall survival of a HER2-positive metastatic breast cancer patient using a bioinformatic-based personalized peptide immunization called BITAP (BioInform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schönharting, Wolfgang, Roehnisch, Tim, Manoochehri, Mehdi, Christoph, Jan, Sieger, Marie, Nogueira, Mauro, Martos-Contreras, Mari Carmen, Kunz, Meik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301538/ https://www.ncbi.nlm.nih.gov/pubmed/37376412 http://dx.doi.org/10.3390/vaccines11061023

Ejemplares similares

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
por: Correa, Isabel, et al.
Publicado: (2001)

Probing the Unknowns in Cytokinin-Mediated Immune Defense in Arabidopsis with Systems Biology Approaches
por: Naseem, Muhammad, et al.
Publicado: (2014)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
por: dos Santos, Giovana Tavares, et al.
Publicado: (2017)

Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model
por: Roehnisch, Tim, et al.
Publicado: (2013)

PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
por: Gschwantler-Kaulich, Daphne, et al.
Publicado: (2017)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors
por: Weide, Rudolf, et al.
Publicado: (2014)

Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma
por: Roehnisch, Tim, et al.
Publicado: (2014)

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
por: Löffler, Markus W., et al.
Publicado: (2016)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
por: Mendes, Diogo, et al.
Publicado: (2015)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2023)

Angiocrine Regulation of Epithelial Barrier Integrity in Inflammatory Bowel Disease
por: Stürzl, Michael, et al.
Publicado: (2021)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
por: Chen, I-Chun, et al.
Publicado: (2021)

Erratum to “Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient”
por: Löffler, Markus W., et al.
Publicado: (2017)

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
por: Witzel, Isabell, et al.
Publicado: (2014)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

HER2–CDH1 Interaction via Wnt/B-Catenin Is Associated with Patients’ Survival in HER2-Positive Metastatic Gastric Adenocarcinoma
por: De Re, Valli, et al.
Publicado: (2022)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

The drug-minded protein interaction database (DrumPID) for efficient target analysis and drug development
por: Kunz, Meik, et al.
Publicado: (2016)

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes
por: Ivanova, Mariia, et al.
Publicado: (2022)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

Metastatic Breast Cancer Survival according to HER2 and Topo2a Gene Status
por: Todorović-Raković, N., et al.
Publicado: (2009)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

Direct analysis of HLA/HER-2 peptide epitopes
por: Patterson, Andrea, et al.
Publicado: (2013)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

HER2-positive Metastatic Melanoma: A Cautionary Tale!
por: Cui, Xiaoyan, et al.
Publicado: (2020)

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
por: Gómez-Martin, Carlos, et al.
Publicado: (2012)

Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer
por: Moilanen, Tiina, et al.
Publicado: (2017)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)
por: Falcon, Silvia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l2f32qs20mi48b1aefnjlirklq